Filtered By:
Specialty: Cancer & Oncology
Condition: Atrial Fibrillation
Nutrition: Vitamin K

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Cancers, Vol. 15, Pages 2574: Systematic Review and Meta-Analysis of Oral Anticoagulant Therapy in Atrial Fibrillation Cancer Patients
Conclusions: Anticoagulation with DOACs provides a higher safety profile with respect to VKAs in terms of stroke reduction and a relative bleeding reduction risk. Further studies are needed to better assess the optimal anticoagulation strategy in cancer patients with AF.
Source: Cancers - April 30, 2023 Category: Cancer & Oncology Authors: Alberto Cereda Stefano Lucreziotti Antonio Gabriele Franchina Alessandra Laricchia Valentina De Regibus Barbara Conconi Matteo Carl à Andrea Spangaro Matteo Rocchetti Luca Ponti Alessandro Minardi Elena Sala Giuseppe Massimo Sangiorgi Gabriele Tumminello Tags: Review Source Type: research

Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?
ConclusionAC did not seem to influence the incidence of ICH in patients with glioblastoma or brain metastases within follow up of just under 9  months.
Source: Journal of Neuro-Oncology - March 5, 2021 Category: Cancer & Oncology Source Type: research

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.
Authors: Cullell N, Carrera C, Muiño E, Torres N, Krupinski J, Fernandez-Cadenas I Abstract Oral anticoagulants (OAs) are the recommended drugs to prevent cardiovascular events and recurrence in patients with atrial fibrillation (AF) and cardioembolic stroke. We conducted a literature search to review the current state of OAs pharmacogenomics, focusing on Genome Wide Association Studies (GWAs) in patients treated with vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). VKAs: Warfarin, acenocoumarol, fluindione and phenprocoumon have long been used, but their interindividual variability and narrow ...
Source: Oncotarget - July 20, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research